Judith A Gilbert. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Antineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useBile Duct Neoplasms/drug therapyBile Duct Neoplasms/geneticsBile Duct Neoplasms/mortalityBile Duct Neoplasms/pathologyCholangiocarcinoma/drug therapyCholangiocarcinoma/geneticsCholangiocarcinoma/mortalityCholangiocarcinoma/pathologyClinical Trials, Phase II as TopicDisease-Free SurvivalHumansMulticenter Studies as TopicMutationPhenylurea Compounds/adverse effectsPhenylurea Compounds/therapeutic usePyrimidines/adverse effectsPyrimidines/therapeutic useReceptors, Fibroblast Growth Factor/geneticsTreatment Outcome
Substances: See more » Antineoplastic AgentsPhenylurea CompoundsPyrimidinesReceptors, Fibroblast Growth Factorinfigratinib
Year: 2017 PMID: 29233557 DOI: 10.1016/S1470-2045(17)30902-6
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316